Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Thursday, 30'th Oct 2025
Zymeworks (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Thursday
02:09am, Thursday, 30'th Oct 2025
Zymeworks (NYSE: ZYME - Get Free Report) is anticipated to issue its results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.28) per share an
Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 29'th Oct 2025
Zymeworks (ZYME) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 28'th Oct 2025
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
09:47pm, Thursday, 23'rd Oct 2025
Zymeworks Inc. (NASDAQ:ZYME ) Shareholder/Analyst Call October 23, 2025 3:30 PM EDT Company Participants Sabeen Mekan - Senior Vice President of Clinical Development Stuart Barnscher Conference Call P
VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. $ZYME Position Trimmed by KLP Kapitalforvaltning AS
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS trimmed its holdings in shares of Zymeworks Inc. (NYSE: ZYME) by 29.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional inv
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade
10:55am, Thursday, 16'th Oct 2025
The mean of analysts' price targets for Zymeworks (ZYME) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
06:00am, Thursday, 16'th Oct 2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?
01:01pm, Tuesday, 14'th Oct 2025
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
08:30am, Thursday, 09'th Oct 2025
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
06:00am, Thursday, 09'th Oct 2025
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On
06:09pm, Tuesday, 02'nd Sep 2025
I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
12:30pm, Tuesday, 02'nd Sep 2025
Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.
